Navigation Links
Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA
Date:2/21/2008

ced, we plan to initiate an international pivotal phase III clinical trial with Alpharadin in HRPC patients during the first half of 2008."

About Algeta

Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology.

Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, is planned to enter Phase III clinical trials in hormone refractory prostate cancer before mid 2008 based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.

Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227.

The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial s
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Francisco, September 15, 2014Prostate cancer patients who received ... quality of life, as well as bladder and ... after RT, according to research presented today at ... Annual Meeting. Additionally, results indicate that parallel quality ... who receive different regimens of HPFX RT. , ...
(Date:9/16/2014)... experimental positron emission tomography (PET) tracer is effective in ... alive, according to a case study conducted at the ... Molecular Neuroimaging (MNI) LLC in New Haven, and published ... , Specifically, the study results suggest that an experimental ... latch onto a protein called tau that accumulates in ...
(Date:9/16/2014)... other workplace incident, a statistic that transport safety experts ... hosted by QUT,s Centre for Accident Research & Road ... Transport Conference (OSIT) to be held on the Gold ... from all facets of transport safety including roads, rail, ... , CARRS-Q research fellow Darren Wishart said the aim ...
(Date:9/16/2014)... risk of getting prostate cancer after a worldwide team ... cancer,s genetic biomarkers, reported in Nature Genetics ... Dr Jyotsna Batra and Distinguished Professor Judith Clements, who ... research hubs around the world, said the teams analysed ... , "It,s the largest analysis of genetic biomarkers ever ...
(Date:9/16/2014)... Non-small cell lung cancer (NSCLC) survivors who never ... time of diagnosis have a lower risk of ... those who are current smokers, suggesting that increased ... of SPLC, according to research presented today at ... Annual Meeting. , The analysis studied the association ...
Breaking Medicine News(10 mins):Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 2Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 3Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:CARRS-Q Host International Transport Safety Conference 2Health News:New gene research helps pinpoint prostate cancer risk 2Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 2Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 3
... , , , , , ... , AUDIO: Researchers at Washington ... Click here for more information. , ... , , , , , ...
... Underage and heavy drinking on college campuses continue to ... as the University of Missouri, have made strides in ... continually trying to educate students about the risks of ... students who viewed images of beer cans packaged and ...
... stimulation technique administered to both sides of the brain ... in their hands and arms, according to a new ... Center (BIDMC). Described in today,s Online Issue ... that stroke patients who received bihemispheric transcranial direct current ...
... , WEDNESDAY, Nov. 10 (HealthDay News) -- Researchers have pinpointed ... who die quickly from acute myeloid leukemia (AML) from those ... Nov. 11 issue of the New England Journal of ... best candidates for more aggressive initial treatment. The insights might ...
... (Garrison, NY) Organizations that seek to provide health care, food, ... in developing countries often face ethical dilemmas: Are they doing ... a corrupt system and ultimately building its capacity to detain ... in an article coauthored by Nancy Berlinger and Michael Gusmano, ...
... is not much better than a death sentence, given a survival ... victim of the ability to breathe. But researchers at the ... that may serve as a marker for a rapidly progressing form ... tissue in the lungs. More than just signaling which patients ...
Cached Medicine News:Health News:Mutations in single gene predict poor outcomes in adult leukemia 2Health News:Mutations in single gene predict poor outcomes in adult leukemia 3Health News:Mutations in single gene predict poor outcomes in adult leukemia 4Health News:Mutations in single gene predict poor outcomes in adult leukemia 5Health News:Mutations in single gene predict poor outcomes in adult leukemia 6Health News:Team colors on cans change perceptions of alcohol risks, MU study finds 2Health News:Noninvasive brain stimulation helps improve motor function in stroke patients 2Health News:Noninvasive brain stimulation helps improve motor function in stroke patients 3Health News:Gene Mutations Seem to Make a Leukemia More Deadly 2Health News:Gene Mutations Seem to Make a Leukemia More Deadly 3Health News:Researchers see ethical dilemmas of providing care in drug detention centers 2Health News:New indicator found for rapidly progressing form of deadly lung disease 2
(Date:9/16/2014)... 16, 2014  Decision Resources Group finds that the rheumatoid arthritis ... 2013 to over $18.2 billion in 2023 in the ... Germany , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug ... but growth will be constrained and patient shares will decline due ...
(Date:9/16/2014)... 2014   Evana Automation Specialists , a leading ... test systems, recently received a contract to provide a ... The Evana solution will help error-proof the process of ... as reduce labor. A catheter adapter, ... assembly cell. The robot will pick the adapter, connector ...
(Date:9/16/2014)... , Sept. 16, 2014 The National ... Institute has simultaneously released the NAMCP Medical Technologies ... Diagnostics Dossier Template © , which provide medical ... for either medical devices or diagnostics that accounts ... each of these technology types (instead of having ...
Breaking Medicine Technology:The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2
... Ind., Nov. 3, 2011 Zimmer Holdings, Inc. (NYSE: ... Anterior Cervical Plate System at the 26th North American ... a generous graft window and narrow waist providing clinicians with ... has a low profile (less than 2mm) which clinical literature ...
... PERKASIE, Pa., Nov. 3, 2011 A new company ... customers for implantable medical devices.  US BioDesign, located in ... medical device OEM firms to broaden the company,s breadth ... founders, Tom Molz – CEO and Skott Greenhalgh – ...
Cached Medicine Technology:Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 2Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 3Newly Launched US BioDesign to Provide OEM Development/Manufacturing Services to Medical Device Customers 2
... onsite test! QuickScreen multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... are highly accurate in detecting the presence of ... by GC/MS testing. This assay provides a preliminary ... as GC/MS) must be used in order to ... applied to any drug of abuse test result, ...
Medicine Products: